Chorioamnionitis occurs in 1% to 5% of term pregnancies and may complicate up to 25% of cases of preterm labor. The traditional regimen used to treat intra-amniotic infection is intravenous ampicillin 2g every 6 hours and intravenous gentamicin 1.5 mg/kg every 8 hrs until delivery . In the past the recommendation has been that the antibiotics be continued postpartum until 24-48 hours afebrile. More recent studies have looked at using a one time dose of antibiotics after delivery vs treating until 24-48 hours afebrile. There have been no studies comparing treatment of chorioamnionitis with antibiotics vs no treatment with antibiotics postpartum. The aim of this study is to compare no treatment vs treatment with one dose after a vaginal delivery and one dose of antibiotics vs a full course until 24 hours afebrile after a cesarean delivery complicated by chorioamnionitis. The hypothesis is that there will be no difference in outcome between the two groups in each arm. This is a randomized study. Once the patient delivers she will be randomized to one of two groups in each arm. First arm (vaginal delivery) A: no treatment, B: treatment with a one time dose of ampicillin/gentamicin; Second arm (c/s) A: one dose of ampicillin/gentamicin/clindamycin, B: treatment with ampicillin/gentamicin and clindamycin until 24 hours afebrile. The goal of the study is to determine the optimal postpartum management of chorioamnionitis.

Further study details as provided by United States Naval Medical Center, Portsmouth:

Primary Outcome Measures:

To determine the courses of antibiotics needed after vaginal delivery and after cesareans in pregnancies complicated by chorioamnionitis. [ Time Frame: Postpartum 24 hours ] [ Designated as safety issue: No ]

one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)

Drug: Ampicillin gentamicin clindamycin

one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)

cesarean multiple antibiotics 4

ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours

Drug: ampicillin gentamicin clindamycin

ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours

Detailed Description:

Chorioamnionitis refers to infection of the amniotic fluid, membranes, placenta and/or uterus. Clinical chorioamnionitis is defined by a temperature of 380 C or more and one or more of the following findings: maternal heart rate > 100 BPM, baseline fetal heart rate > 160 BPM, uterine tenderness, or foul smelling amniotic fluid. It complicates 0.5 to 10.5 percent of deliveries and accounts for 10 to 40 percent of cases of maternal febrile morbidity in the peripartum period and 50 percent of preterm deliveries before 30 weeks of gestation. Chorioamnionitis is also associated with 20 to 40 percent of cases of early neonatal sepsis and pneumonia. (Hagberg et al). The most extensively tested antibiotic regimen is ampicillin 2 g IV every 6 hours and gentamicin 1.5mg/kg every 8 hours. After delivery clindamycin 900 mg IV q 8 hours can be used for further coverage in those women delivering by cesarean section. The treatment is usually continued until the patient is asymptomatic for 24 - 48 hours although that treatment is primarily based on expert opinion. (Edwards et al). Potential benefits of not needing to treat with antibiotics after a delivery complicated by intramniotic infection is shortened hospital stay and reduced cost. No studies up until now have compared treatment verses no treatment head to head for vaginal delivery and one postpartum dose vs. continued treatment for 24 hours in the women undergoing a cesarean delivery. Unfortunately the Duff study combined patients analyzing both vaginal deliveries and cesarean deliveries together. They were both treated with either the single dose of antibiotics or continual treatment with antibiotics until afebrile and asymptomatic for 24 hours. He found no statistical significant difference in treatment failure in the one dose vs. multiple dose groups. This finding was the primary outcome of the study.Our study will be a double blind placebo controlled randomized study. There will be two arms: vaginal delivery and cesarean delivery. The first arm consists of patients who have had a vaginal delivery complicated by chorioamnionitis. They will be randomized into one of two groups: 1) no further antibiotics after delivery ( they will receive a saline infusion instead of antibiotics but this will be labeled in the pharmacy and neither the patient nor the physician will know whether the patient is receiving antibiotics or saline) or 2) one additional dose of antibiotics (ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV) following their vaginal delivery. The second arm of this study consists of patients who have had a cesarean delivery complicated by chorioamnionitis. They will also be randomized into one of two groups: 1) one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics but this will be labeled in the pharmacy and neither the patient or the physician will know whether the patient is receiving antibiotics or saline) or 2) ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours. For the patients in both arms of the study the primary outcome will be treatment failure defined as either a single temperature of 39 C or two or more temperatures of 38.4 C or more at least 4 hours apart after delivery in the vaginal group or after the first antibiotic dose in the cesarean group. All treatment failures will be treated with ampicillin 2 grams IV every 6 hours, gentamicin 1.5 mg/kg every 8 hours and clindamycin 900 mg every 8 hours until the patient has been afebrile and asymptomatic for 24 hours. Timing of temperature spikes or other symptoms associated with uterine infection will be noted as well as number of doses of antibiotics and infection related complications such as wound infection, pelvic abscess and septic pelvic thrombophlebitis. Patients will be recruited from the Labor and Delivery unit here at Naval Medical Center Portsmouth. All patients that develop chorioamnionitis will be offered participation in the study. All women greater than 18 years old will be eligible to participate. Patients will be consented by the residents and staff working on labor and delivery. Exclusion criteria will include those who do not wish to participate, patients who are allergic to the study antibiotics, women who are immunocompromised or women receiving antibiotics for other reasons such as prophylaxis for bacterial endocarditis.

Eligibility

Ages Eligible for Study:

18 Years to 45 Years

Genders Eligible for Study:

Female

Accepts Healthy Volunteers:

Yes

Criteria

Inclusion Criteria:.

All patients that develop chorioamnionitis and who are over 18 years of age will be offered participation in the study.

Exclusion Criteria:

Women who do not wish to participate, patients who are allergic to the study antibiotics

Women who are immunocompromised or women receiving antibiotics for other reasons such as prophylaxis for bacterial endocarditis

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00814905